Maria L. Brandi
Elite in Hyperparathyroidism

Maria L. Brandi

Florence, IT 
Elite in Hyperparathyroidism
Florence, IT 
OverviewLocationsClinical Research

Overview

Maria Brandi practices in Florence, Italy. Brandi is rated as an Elite expert by MediFind in the treatment of Hyperparathyroidism. Their top areas of expertise are Osteoporosis, Hypophosphatemia, X-Linked Hypophosphatemia, Parathyroidectomy, and Hormone Replacement Therapy (HRT).

Their clinical research consists of co-authoring 547 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 46 articles in the study of Hyperparathyroidism.

Locations

Florence, Italy
Other Locations
Milan, Italy
Sesto Fiorentino, Italy
San Gallo, Italy
Rome, Italy
Italy
Brindisi, 72023, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological
Study Drug: rhPTH(1-84)
Study Phase: Phase 4
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
Enrollment Status: Completed
Publish Date: May 20, 2022
Intervention Type: Drug
Study Drug: Burosumab
Study Phase: Phase 3
View 2 Less Clinical Trials

547 Total Publications

Correction: Experts' consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan.
Correction: Experts' consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan.
Journal: Journal of endocrinological investigation
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Brandi's expertise for a condition
ConditionClose
View All 16 Elite Conditions
View All 12 Distinguished Conditions
View All 22 Advanced Conditions
View All 61 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile